Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Bio-Techne ...
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx ...
Fear of recurrence among uninsured and underrepresented prostate cancer survivors of the Men's Health Study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of ...
MDxHealth offers non-invasive liquid and tissue-based tests for prostate cancer It was a milestone second quarter for precision diagnostics company MDxHealth SA. The company achieved its first quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results